Intervista a Giuliana Vallanti, Direttore Sviluppo, Controllo Qualità sulle terapie antitumorali derivate dalle cellule CAR-NK
aboutpharma_intervistagv_car_nk_aprile2019.pdf224.16 KBDear Users, we would like to inform you that, as of 30 September, AGC Biologics S.p.A. (formerly MolMed S.p.A.) is no longer listed on the Milan Stock Exchange and has become part of the AGC Biologics Group. For any information on the company and the group, you are kindly invited to consult the websitewww.agcbio.com.
The contents present on this portal (www.molmed.com) are updated until the date of September 30, 2020 and will be available for the time frame foreseen by applicable regulations.
In addition, the "work with us" section is still active, while the contact details are no longer accessible.
